Do investigational MET inhibitors have potential for the treatment of gastric cancer?

References

• Zhang YW, Vande Woude GF. HGF/SF-Met signaling in the control of branching morphogenesis and invasion. J Cell Biochem. 2003. DOI:10.1002/jcb.10358.
   Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.
   PubMed Web of Science ®Google Scholar
• Go H, Jeon YK, Park HJ, et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5:305–313.
   PubMed Web of Science ®Google Scholar
• Peng Z, Zhu Y, Wang Q, et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One. 2014;9:e84502.
   PubMed Web of Science ®Google Scholar
• Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012;18:2269–2277.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2008;20:298–304.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658–673.
   PubMed Web of Science ®Google Scholar
• Corso S, Ghiso E, Cepero V, et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 2010;9:121.
   PubMed Web of Science ®Google Scholar
• Paulson AK, Linklater ES, Berghuis BD, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res. 2013;11:1112–1121.
   PubMed Web of Science ®Google Scholar
• New global cancer data: GLOBOCAN. UICC n.d. 2018 [cited 2019 Jan 2]. Available from: https://www.uicc.org/new-global-cancer-data-globocan-2018
   Google Scholar
• Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–4810.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang X, Xin Y. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 2011;26:1111–1120.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1021–1027.
   PubMed Web of Science ®Google Scholar
• Watermann I, Schmitt B, Stellmacher F, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015;10:130.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Ang A, Liao W-L, et al. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer. 2017;123:1061–1070.
   PubMed Web of Science ®Google Scholar
• Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15:1007–1018.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1467–1482.
   PubMed Web of Science ®Google Scholar
• Doi T, Kang Y-K, Muro K, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the RILOMET-2 trial. J Clin Oncol. 2015;33:TPS226–TPS226.
   Web of Science ®Google Scholar
• Salgia R, Patel P, Bothos J, et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014;20:1666–1675.
   PubMed Web of Science ®Google Scholar
• Shah MA, Cho J-Y, Tan IB, et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction. Oncologist. 2016;21:1085–1090.
   PubMed Web of Science ®Google Scholar
• Shah MA, Bang Y-J, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma. JAMA Oncol. 2017;3:620.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Henderson L, Xiao S-Y, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011;1:573–579.
   PubMed Web of Science ®Google Scholar
• Kwak EL, LoRusso P, Hamid O, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol. 2015;33:1.
   PubMed Web of Science ®Google Scholar
• Mandiyan S, Robinson BS, Kimmel L, et al. Blocking act. a nov. anti-met humaniz. monoclon. antibody, KTN0216, is enhanc. by IgG2 isotype HGF-dependent met-amplified tumors. [abstract]. Proc 106th Annu Meet Am Assoc Cancer Res. 2015. DOI:10.1158/1538-7445.AM2015-1696.
   Google Scholar
• Scagliotti GV, Moro-Sibilot D, Kollmeier J, et al. A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatm. J Clin Oncol. 2017 May 20;35(No 15_suppl):9019–9019 n.d.
   Google Scholar
• Pennacchietti S, Cazzanti M, Bertotti A, et al. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res. 2014;74:6598–6609.
   PubMed Web of Science ®Google Scholar